A Level Politics - Pressure Groups- Drug companies: ‘big pharma’ and the FDA

A Level Politics - Pressure Groups- Drug companies: ‘big pharma’ and the FDA
This section examines the complex relationship between Big Pharma (large pharmaceutical companies) and two key players in the US regulatory landscape: the Food and Drug Administration (FDA) and Congress. The core issue revolves around potential regulatory capture, where regulatory bodies become overly influenced by the industries they are meant to regulate.
I. Key Players & Their Interactions:

• Big Pharma: Large pharmaceutical companies actively cultivate relationships with both the FDA and Congress to influence policy and regulations favorable to their business interests. This influence extends to campaign donations and lobbying efforts.
• FDA (Food and Drug Administration): The federal agency responsible for regulating pharmaceuticals. Its independence is crucial for public health and safety, yet its susceptibility to influence from Big Pharma is a significant concern.
• Congress (Specifically, House Energy Subcommittee on Health): Congressional committees, like the House Energy Subcommittee on Health, wield considerable power over pharmaceutical regulations and funding. Big Pharma invests heavily in influencing these committees through campaign donations. The example provided highlights the significant donations received by Rep. Anna Eshoo.

II. Mechanisms of Influence:

• Campaign Donations: Big Pharma makes substantial campaign contributions to key members of Congress, particularly those on committees overseeing health-related legislation. This creates a potential for quid pro quo relationships, where political favors are exchanged for financial support.
• The Revolving Door: The "revolving door" phenomenon describes the movement of individuals between positions of regulatory power (e.g., the FDA) and the industries they regulate (Big Pharma). The example of Scott Gottlieb illustrates this: he worked for the FDA, then for pharmaceutical companies, and finally returned to a leadership position at the FDA before joining a major pharmaceutical company's board. This creates potential conflicts of interest and raises concerns about regulatory capture.

III. Concerns & Critical Analysis:

• Regulatory Capture: The close ties between Big Pharma, the FDA, and Congress raise serious concerns about regulatory capture. This means the regulatory process may prioritize the interests of the pharmaceutical industry over the public interest, potentially leading to lax regulations, higher drug prices, and less effective oversight.
• Conflicts of Interest: The revolving door phenomenon and campaign donations create clear conflicts of interest that undermine the integrity of the regulatory system.
• Public Health Implications: Regulatory capture can lead to negative consequences for public health, including delayed or ineffective regulation of potentially dangerous drugs, inflated drug prices, and limited access to essential medications.

IV. Study Questions:

1. Define regulatory capture and explain how it applies to the relationship between Big Pharma and the FDA.
2. Analyze the role of campaign donations in influencing regulatory decisions related to pharmaceuticals.
3. Explain the significance of the “revolving door” phenomenon and its potential impact on regulatory integrity.
4. Discuss the potential public health consequences of a captured regulatory system.
5. Propose solutions to mitigate the influence of Big Pharma on the FDA and Congress.

To learn more about A Level Politics Click Here